THE EFFECT OF EMPAGLIFLOZIN AND RANOLAZINE ON THE DYNAMICS OF STRUCTURAL AND FUNCTIONAL PARAMETERS OF THE HEART AND LEVELS OF BIOMARKERS NT-proBNP AND SOLUBLE (s)ST-2 IN PATIENTS WITH ATRIAL FIBRILLATION AND HEART FAILURE

Atrial fibrillation (AF) is the most common long-term arrhythmia worldwide and has a strong association with heart failure (HF).Aim. To investigate the effect of empagliflozin and ranolazine in addition to standard therapy on the dynamics of structural and functional parameters of the heart and levels of biomarkers NT-proBNP and soluble (s)ST-2 in patients with atrial fibrillation and heart failure.Materials and Methods. We examined 300 patients aged 45-65 years. All patients were divided into groups: Group I - patients with HF without AF (n=150). Group II - patients with HF and AF (permanent form) (n=150). Group of 136 practically healthy individuals. All patients underwent clinical examination, echocardiography (Echo), determination of NT-proBNP and (s)ST-2 levels by enzyme-linked immunosorbent assay.Results. The dynamics of parameters of the LV in the main group was more significant compared to the control group (p<0.05). After treatment, the concentration of circulating NT-ProBNP in the control group decreased by an average of 26.2% (p<0.05), and in the main group of patients - by 15.9% (p<0.05). As for the blood levels of the (s)ST-2 biomarker, after treatment in the control group there was an average decrease of 13.1% (p<0.05) compared with the dynamics in the main group of patients - by 38.8% (p<0.05).Conclusions. The use of INSKTG-2 empagliflozin against the background of standard therapy of heart failure reduction of myocardial remodelling and increase ejection fraction. Complex treatment with empagliflozin and ranolazine as INZCTG-2 helps to reduce the level of NT-ProBNP and (s)ST-2 in the blood serum.